P01.041 Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma

BACKGROUND: Thrombocytopenia is a major adverse event of temozolomide (TMZ) chemotherapy. It may lead to dose reduction/interruption or bleeding. Platum (NCT02227576) was a phase II open label, multicenter single arm trial evaluating the thrombopoetin receptor agonist, romiplostim, for secondary pre...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Le Rhun, E, Devos, P, Houillier, C, Cartalat-Carel, S, Chinot, O, Di Stefano, A, Reyns, N, Dubois, F, Weller, M
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Poster Presentations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144386/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.083
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires